Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Maximilian, Julve"'
Introduction: Despite the recent advances in the treatment of malignant melanoma with immunotherapy and BRAF/MEK targeted agents, advanced disease still beholds a poor prognosis for a significant proportion of patients. Cyclin-dependent kinase (CDK)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62f43c47538c9f149d468e915c8b4854
http://hdl.handle.net/10044/1/83813
http://hdl.handle.net/10044/1/83813
Publikováno v:
BMJ Case Rep
A 69-year-old man with a background of hypertension, benign prostatic hypertrophy and Eastern Cooperative Oncology Group (ECOG) performance status 0, presented with abdominal pain and weight loss in May 2018. Biochemistry and full blood count were un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75105a2aa014f7d15b2212cb0de02e98
https://pubmed.ncbi.nlm.nih.gov/32265211
https://pubmed.ncbi.nlm.nih.gov/32265211
Autor:
Ellis Dell, Alexandra Hadjimichalis, Mark Openshaw, Maximilian Julve, T. Newsom-Davis, Stephanie Slater, Ruth Caulkin
Publikováno v:
Lung Cancer. 156:S20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10d7a0a1782679fa1463df91fcf4cfd5
https://doi.org/10.1016/s0169-5002(21)00246-4
https://doi.org/10.1016/s0169-5002(21)00246-4
Autor:
Sanjay Popat, Maximilian Julve, James Clark, T. Newsom-Davis, Ellis Dell, Adam Januszewski, Ravindhi Murphy
Publikováno v:
Web of Science
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::874da0d29addbc337c28024d5dba170e
https://doi.org/10.1016/s0169-5002(21)00382-2
https://doi.org/10.1016/s0169-5002(21)00382-2
Autor:
Gerard Walls, James Larkin, E. Kalaitzaki, Lavinia Spain, Maximilian Julve, K. O’Meara, Jeremy Rees, M. E. Gore, Samra Turajlic, Thomas A. Schmid
Publikováno v:
Annals of Oncology. 28:377-385
Background: Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved following large Phase III trials. Immunerelated n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02582b5e0f37f5bf60c46170a8dca4a2
https://doi.org/10.1093/annonc/mdw558
https://doi.org/10.1093/annonc/mdw558
Autor:
Petros Grivas, Jonathan Krell, Maximilian Julve, Mark P. Lythgoe, Philip Savage, Ali Raza Khaki
Publikováno v:
Journal of Clinical Oncology. 39:22-22
22 Background: GU cancers account for 1 in 5 of new cancer diagnoses in the USA. Significant racial disparities exist in terms of incidence, treatment and outcomes. Current FDA clinical trial guidance advises race reporting as a minimum of 5 categori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::256de7ebb9ec38db522565059d730595
https://doi.org/10.1200/jco.2021.39.6_suppl.22
https://doi.org/10.1200/jco.2021.39.6_suppl.22
Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations
Publikováno v:
Expert opinion on pharmacotherapy. 17(7)
In the 40-50% of advanced melanoma patients with tumors harboring BRAF V600E and V600 K mutations, BRAF inhibitors such as dabrafenib are a highly effective treatment. However, most patients develop resistance after several months on treatment. The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d4563363132aab40fc4f4a4eefaeed8
https://pubmed.ncbi.nlm.nih.gov/27027150
https://pubmed.ncbi.nlm.nih.gov/27027150
Publikováno v:
BMJ case reports. 2014
A 77-year-old man with known adenocarcinoma of the gastro-oesophageal junction presented with symptoms of general deterioration associated with right-sided retro-orbital pain and visual disturbance. The visual acuity in the right eye was normal but t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a987b6d79b8fa01f35245aab316399
https://pubmed.ncbi.nlm.nih.gov/25115784
https://pubmed.ncbi.nlm.nih.gov/25115784
Autor:
Neha, Chopra, Fatima, El-Khouly, Maximilian, Julve, Robert, Goldstein, Astrid, Mayer, Christina, Thirlwell, Tim, Meyer, Roopinder, Gillmore
Publikováno v:
In Annals of Oncology June 2014 25 Supplement 2:ii45-ii45